1 The effects of single oral doses of a new selective P2-adrenoceptor agonist procaterol (0.05 mg and 0.1 mg) and salbutamol (4 mg) on ventilatory function, were compared in 24 asthmatic patients. 2 A bronchodilator effect of similar duration and magnitude followed all three treatments with no evidence of a dose-related response in the case of procaterol. 3 There was no significant difference in blood pressure or heart rate responses or pattern of unwanted effects. 4 We conclude that procaterol and salbutamol are clinically similar with oral dosing and that the maximum effective dose of procaterol is not greater than 0.05 mg.
Introduction
Procaterol, 5-(hydroxy-2-isopropylaminobutyl)-8-hydrocarbostyril hydrochloride hemihydrate (Figure 1) , is a new P2-selective adrenoceptor agonist, which has been under investigation in the United States and clinical studies indicate that it is an effective bronchodilator in asthmatic patients (Zanetti et al., 1982) . Both in vitro and in vivo animal studies (Himori & Tairi, 1977; a HOCH2 CH3 HO()CHCOH-CH2NHIOC;LH3
UH3
Youichi & Yabuuchi, 1977; Yabuuchi, 1977) suggest that procaterol is not only more potent but also has a longer duration of action than salbutamol. The purpose of the present study was to compare the cardiorespiratory activity, duration of action and pattern of unwanted effects of procaterol and salbutamol in asthmatics. Baseline FVC (mean ± s.e. mean) values were procaterol (0.05 mg) 2.28 ± 0.03 1, procaterol (0.1 mg) 2.36 + 0.03 1 and salbutamol 2.13 ± 0.04 1). The change in FVC were quantitatively similar to those for FEVy (Figure 3) .
Following isoprenaline sulphate a significant increase from pre-inhalation response was observed at each post-inhalation assessment with each treatment (P < 0.01). Maximum mean increase in FEV1 with isoprenaline were 36%, 37%, 37% after procaterol 0.05 mg, 0.1 mg and salbutamol respectively. There was no significant difference between the peak responses after drug and isoprenaline sulphate inhalation.
Lying and standing systolic and diastolic (Figure 4 ) blood pressure decreased following procaterol 0.1 mg and salbutamol. Mean changes were less than 8 mm Hg and there was no overall difference in treatment response. Supine heart rate showed no significant change from baseline throughout the assessment period.
Unwanted effects and their incidence with each treatment are set out in Table 1 (----) . Values shown are the mean for 24 patients. (Whitsett et al., 1981) . The majority of unwanted effects such as tremor, headache and palpitations are those normally associated with P-adrenoceptor agonist. The overall incidence of unwanted effects was similar with the two drugs in this study. It is notable that seven of eight patients who experienced tremor had not been receiving oral P-adrenoceptor agonists whereas, of the fourteen patients who were receiving these only one encountered tremor. The decrease in these problems with continuing therapy is well recognised (Larsson, 1977) .
We conclude that this study showed no significant difference between procaterol and salbutamol in cardiorespiratory activity, duration of action or incidence of unwanted effects. In fact the pattern of activity with the two drugs is strikingly similar.
